Table 1.
Temporal span of recruitment and type of treatment.
| Gender | N° (%) | ||
|---|---|---|---|
| Male | 1328 (63) | ||
| Female | 766 (37) | ||
| Recruitment period (years) | |||
| 1997–2002 | 148 (7) | ||
| 2003–2008 | 515 (24.6) | ||
| 2009–2016 | 1431 (68.4) | ||
| Concomitant Chemotherapy schedule | |||
| One-drug | 1585 (75.7) | ||
| Capecitabine | 1044 (65.8) | ||
| 5-FU | 519 (32.7) | ||
| TT* | 21 (1.3) | ||
| Oxaliplatin | 1 (0.06) | ||
| Two-drugs | 509 (24.3) | ||
| 5-FU + Oxaliplatin | 201 (39.5) | ||
| Capecitabine + Oxaliplatin | 192 (37.8) | ||
| Raltitrexed + Oxaliplatin | 70 (13.8) | ||
| Capecitabine + TT | 28 (5.5) | ||
| 5-FU + Mitomicin-C | 11 (2.1) | ||
| 5-FU + TT | 7 (1.3) | ||
| Radiotherapy median dose, range (cGy) | 5040 (2660–6000) | ||
| Patients irradiated with ≤5040 cGy | 1560 (74.5) | ||
| Patients irradiated with >5040 cGy | 534 (25.5) |
*
TT = target therapy (Panitumumab, Cetuximab, Bevacizumab, Gefitinib).